Financial

Corindus Reports Second Quarter 2019 Results

Corindus announced today a definitive agreement to be acquired by Siemens Healthineers for approximately $1.1 billion, or $4.28 per share, in an all-cash transaction Second quarter revenue of $4.6 million reflects increasing adoption and utilization in U.S. and abroad WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer […]

Pomerantz Law Firm Announces the Filing of a Class Action against ABIOMED, Inc. and Certain Officers – ABMD

NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against ABIOMED, Inc. (“ABIOMED” or the “Company”) (NASDAQ:  ABMD) and certain of its officers.   The class action, filed in United States District Court, for the Southern District of New York, and […]

Proteon Therapeutics Announces Second Quarter 2019 Financial Results

WALTHAM, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) — Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular disease, today announced its financial results for the quarter ended June 30, 2019, and recent […]

Caladrius Biosciences and Cognate BioServices Establish Manufacturing Agreement for Phase 3 Confirmatory Pivotal Clinical Trial of CLBS14 in No-option Refractory Disabling Angina

BASKING RIDGE, N.J. and MEMPHIS, Tenn., Aug. 07, 2019 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, and Cognate BioServices, Inc. (“Cognate”), a leading contract development and manufacturing organization in […]

XyloCor Therapeutics Names Rickey Reinhardt, MD, PhD, Chief Medical Officer

PHILADELPHIA–(BUSINESS WIRE)–XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for unmet needs in cardiovascular disease, strengthens its leadership team with the appointment of Rickey Reinhardt, MD, PhD, as Chief Medical Officer. Dr. Reinhardt formerly served as Chief Medical Officer for Comet Therapeutics where he […]

Shockwave Medical Reports Second Quarter 2019 Financial Results

SANTA CLARA, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2019. Recent Highlights Recognized revenue of $10.0 million […]